Accelerating Scientific Discovery with AI: Our Investment in Causaly
“The characteristic of scientific progress is our knowing that we did not know” – Gaston Bachelard
By: Calvin Yeoh, Caroline Xie, and Seth Pierrepont | July 13, 2023
Causaly co-founders Yiannis Kiachopoulos and Artur Saudabayev.
The pharmaceutical industry has achieved monumental breakthroughs in revolutionizing healthcare, raising the quality of life for millions globally. Behind the scenes, however, the process of biomedical research itself remains highly manual and effort-intensive. Drug development timelines often span over a decade and scientists continually struggle to process the onslaught of data delivered by R&D.
At ICONIQ Growth, we believe effective scientific innovation and discoveries are rooted in comprehensive and timely access to information. In order to pursue research in an efficient manner, scientists should be empowered with both information at their fingertips and the ability to quickly gain a thorough understanding of new developments.
In that spirit, we’re proud to announce our partnership with Causaly, the London-based, AI-powered search engine and workspace for scientists. We are excited to lead Causaly’s $60 million Series B alongside existing investors Index Ventures, Pentech, Marathon, and EBRD, as well as new investors and experienced operators including Alex Gorsky (former Executive Chairman and CEO, Johnson & Johnson) and Olivier Pomel (CEO and co-founder, Datadog).
Causaly co-founder and CEO Yiannis Kiachopoulos captivated us with his enthusiasm and deep intellectual curiosity toward understanding the world and democratizing access to that knowledge. Together with Artur Saudabayev, Causaly’s co-founder and CTO, they created the engine underlying Causaly’s unique platform today, using AI at its core to extract and codify knowledge. In 2018, they founded Causaly to transform how humans find, visualize, and collaborate on scientific evidence, starting with drug discovery and life sciences as the initial frontier.
Leveraging AI, Causaly is able to codify how humans express relationships in natural languages. The platform automatically ingests and extracts knowledge across massive quantities of scientific literature, which are refined and represented hierarchically within its large and growing proprietary knowledge graph. A scientist would normally spend weeks poring through all of this literature and may still only scratch the surface—with Causaly, that same scientist can now ask questions in natural language and quickly get answers, with full traceability and auditability of results at every step. The value of Causaly’s technology is abundantly evident and resonates across its customer base, which includes 12 of the top 20 pharma companies, such as Novo Nordisk and Gilead.
At ICONIQ Growth, we are proud to be partnering with platforms accelerating life-saving therapies to patients including Benchling, Reify Health, Komodo Health, and Apprentice. Causaly’s platform enables scientists at the forefront of life sciences research and AI to continue pushing the very boundaries of science and drive significant acceleration across the drug development lifecycle.
We have long been supporters of the European technology ecosystem, and we are excited to continue deepening our commitment to entrepreneurs based in Europe with global ambitions such as Causaly.
We are thrilled to partner with Yiannis, Artur, and the entire Causaly team as they continue to enable and accelerate scientific research across life sciences and beyond.
The views expressed in this presentation are those of ICONIQ Growth ("ICONIQ" or the "firm"), are the result of proprietary research, may be subjective, and may not be relied upon in making an investment decision. This presentation is for educational purposes only and does not constitute investment advice or an offer to sell or a solicitation of an offer to buy any securities which will only be made pursuant to definitive offering documents and subscription agreements, including, without limitation, any investment fund or investment product referenced herein. Any reproduction or distribution of this presentation in whole or in part, or the disclosure of any of its contents, without the prior consent of ICONIQ, is prohibited. This presentation may contain forward-looking statements based on current plans, estimates and projections. The recipient of this presentation ("you") are cautioned that a number of important factors could cause actual results or outcomes to differ materially from those expressed in, or implied by, the forward-looking statements. The numbers, figures and case studies included in this presentation have been included for purposes of illustration only, and no assurance can be given that the actual results of ICONIQ or any of its partners and affiliates will correspond with the results contemplated in the presentation. No information is contained herein with respect to conflicts of interest, which may be significant. The portfolio companies and other parties mentioned herein may reflect a selective list of the prior investments made by ICONIQ. Certain of the economic and market information contained herein may have been obtained from published sources and/or prepared by other parties. While such sources are believed to be reliable, none of ICONIQ or any of its affiliates and partners, employees and representatives assume any responsibility for the accuracy of such information. All of the information in the presentation is presented as of the date made available to you (except as otherwise specified), and is subject to change without notice, and may not be current or may have changed (possibly materially) between the date made available to you and the date actually received or reviewed by you. ICONIQ assumes no obligation to update or otherwise revise any information, projections, forecasts or estimates contained in the presentation, including any revisions to reflect changes in economic or market conditions or other circumstances arising after the date the items were made available to you or to reflect the occurrence of unanticipated events. For avoidance of doubt, ICONIQ is not acting as an adviser or fiduciary in any respect in connection with providing this presentation and no relationship shall arise between you and ICONIQ as a result of this presentation being made available to you. ICONIQ is a diversified financial services firm and has direct client relationships with persons that may become limited partners of ICONIQ funds. Notwithstanding that a person may be referred to herein as a "client" of the firm, no limited partner of any fund will, in its capacity as such, be a client of ICONIQ. There can be no assurance that the investments made by any ICONIQ fund will be profitable or will equal the performance of prior investments made by persons described in this presentation.